Supernus announced that the Food and Drug Administration (FDA) has granted tentative approval to the supplemental New Drug Application (sNDA) proposing a label expansion for Trokendi XR (topiramate) extended-release capsules to include prophylaxis of migraine headache in adults.
{iframe}http://www.empr.com/news/fda-grants-tentative-approval-for-trokendi-xr-in-migraine-prophylaxis/article/517481/{/iframe}